Chae Miller
Primary Care · Hackensack, NJNPI 1073050076
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 506 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by SK Life Science, Inc. at 25.7% of the total. Among primary care clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 506 payments — averaging $12.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$2K
- UCB, Inc.$2K
- Neurelis, Inc.$1K
- Jazz Pharmaceuticals Inc.$562
- Aucta Pharmaceuticals, Inc.$220
- Eisai Inc.$219
- plus $1K from 19 others
What the payments were for
- Food & beverage$6,511100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 118 | $1,672 |
| UCB, Inc. | 95 | $1,571 |
| Neurelis, Inc. | 115 | $1,082 |
| Jazz Pharmaceuticals Inc. | 71 | $562 |
| Aucta Pharmaceuticals, Inc. | 18 | $220 |
| Eisai Inc. | 16 | $219 |
| Sumitomo Pharma America, Inc. | 11 | $168 |
| Otter Pharmaceuticals, LLC | 20 | $159 |
| Nobelpharma America, LLC | 6 | $132 |
| Pyros Pharmaceuticals, Inc. | 1 | $111 |
| E.r. Squibb & Sons, L.L.C. | 1 | $93 |
| Aprecia Pharmaceuticals, LLC | 6 | $80 |
| Bristol Myers Squibb | 5 | $75 |
| Catalyst Pharmaceuticals, Inc. | 4 | $60 |
| Azurity Pharmaceuticals, Inc. | 3 | $50 |
| Aquestive Therapeutics, Inc. | 3 | $41 |
| Pfizer | 2 | $37 |
| OWP Pharmaceuticals, Inc. | 2 | $32 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| Ultragenyx Pharmaceutical Inc. | 2 | $28 |
| Biomarin Pharmaceutical Inc. | 1 | $26 |
| Biocodex, Inc. | 1 | $22 |
| Livanova USA, Inc. | 1 | $20 |
| PTC Therapeutics, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIGPODER$111
How this compares
$6,518 in reported general payments places this provider in the 95th percentile of 330 primary care providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 28 | $160,652 |
| BriviactBrivaracetam | 76 | $147,579 |
| XcopriCenobamate | 92 | $134,717 |
| VimpatLacosamide | 102 | $111,317 |
| KeppraLevetiracetam | 35 | $57,862 |
| TopamaxTopiramate | 31 | $47,497 |
| AptiomEslicarbazepine Acetate | 17 | $32,759 |
| TrileptalOxcarbazepine | 17 | $28,716 |
| ValtocoDiazepam | 20 | $20,180 |
| Lacosamide | 199 | $19,270 |
| NayzilamMidazolam | 17 | $15,844 |
| LamictalLamotrigine | 14 | $15,412 |
| Tegretol XrCarbamazepine | 20 | $7,122 |
| Oxcarbazepine | 69 | $6,825 |
| Levetiracetam | 118 | $5,316 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Vimpat, Nayzilam | $1,571 | $274,741195 claims |
| SK Life Science, Inc.Xcopri | $1,672 | $134,71792 claims |
| Neurelis, Inc.Valtoco | $1,082 | $20,18020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 330 primary care providers in New Jersey.
Other primary care in Hackensack
- Linda DavtHackensack$5K
- Ryan VisbeenHackensack$3K
- Kimberly PerdomoHackensack$3K
- Michael Zito GovertNeptune$61K
- Roseann BenantiEnglewood$24K
- Marcelo MarinEnglewood$17K
- Jennifer EdwardsPrinceton$14K
- Mary Grace TolentinoJersey City$9K
- Kevin Robert ReyladoNorth Arlington$8K
- Carlo SebelloJersey City$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.